New three-drug combination treatment achieves notable responses in patients with advanced HER2-negative breast cancer
15 Feb 2024
Treatment in a recent study combined a histone deacetylase (HDAC) inhibitor - a drug that causes a chemical change to stop tumor cells from dividing - with two types of immunotherapy known as checkpoint inhibitors, which unharness the power of the immune response against cancer.
UCC Futures
Todhchaíochtaí UCC
Contact us
Office of Vice President for Research and Innovation | 4th Floor | Block E, Food Science Building | UCC,